Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189880 | 0.92 | CA12 (0.35) | CA12CA1CA2ECE1DPP4 | |
| SCHEMBL1274426 | 0.92 | CA12 (0.35) | CA12CA1CA2ECE1DPP4 | |
| SCHEMBL8745360 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL619330 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL6136334 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL15499 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL7568157 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL8346127 | 0.89 | ALDH1A1 (0.40) | CA12CA1CA2ECE1 | |
| SCHEMBL10659991 | 0.84 | SLC7A5 (0.42) | TERT | |
| Hydrochloric Acid SCHEMBL10664913 | 0.82 | SLC7A5 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222509-A1 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT | AMYLIN PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3524261-A1 | EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT | Amylin Pharmaceuticals, LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180333468-A1 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT | AMYLIN PHARMACEUTICALS, LLC (US) | 2018-11-22 | — | — | US | disclosed |
| US-9884092-B2 | Methods for treating diabetes and reducing body weight | AMYLIN PHARMACEUTICALS, LLC (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160271225-A1 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT | AMYLIN PHARMACEUTICALS, LLC | 2016-09-22 | — | — | US | disclosed |
| EP-2303313-B1 | EXENDINS TO LOWER CHOLESTROL AND TRIGLYCERIDES | AMYLIN PHARMACEUTICALS LLC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150238568-A1 | EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDES | AMYLIN PHARMACEUTICALS, LLC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150157725-A1 | TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINS | ASTRAZENECA PHARMACEUTICALS LP | 2015-06-11 | — | — | US | disclosed |
| US-20150152158-A1 | METHODS TO RESTORE GLYCEMIC CONTROL | AMYLIN PHARMACEUTICALS, LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150150948-A1 | METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHT | ASTRAZENECA PHARMACEUTICALS LP | 2015-06-04 | — | — | US | disclosed |
| EP-1054594-A1 | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000066629-A1 | MODIFIED EXENDINS AND EXENDIN AGONISTS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-1032587-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-2000041548-A2 | METHODS FOR GLUCAGON SUPPRESSION | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041546-A2 | NOVEL EXENDIN AGONIST FORMULATIONS AND METHODS OF ADMINISTRATION THEREOF | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0996459-A1 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999040788-A1 | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999025728-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1998030231-A9 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE | — | 1998-11-12 | — | — | WO | disclosed |
| WO-1998030231-A1 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-07-16 | — | — | WO | disclosed |